Neuroimmunology is entering a defining moment. With the $470M buyout of Vigil’s TREM2 asset, Ventus’ NLRP3 inhibitor in phase 2a, and promising phase 3 BTKi readouts from Sanofi and Roche, the field is beginning to show encouraging signs of clinical viability in targeting neuroinflammation. Now the real race begins. Uncovering the next wave of mechanisms, biomarkers, and translational strategies that will move beyond today’s successes and unlock new therapeutic frontiers in neurodegeneration and neuroimmune-driven psychiatric disease.

Date and Time: Tuesday, 14 April 2026 at 09:00 – Thursday, 16 April 2026 at 17:00

Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States

Prices:
USD 2699.00 – USD 5197.00